PARIS — Results from the REMAIN long-term follow-up study on MCO-010, an optogenetic therapy for retinitis pigmentosa, showed durable efficacy over 3 years.
“This is the most disruptive therapy currently,” Jordi Monés, MD, PhD, told Healio at the Euretina congress. “It is very unique because most of the therapies we have nowadays prevent loss but don’t restore [vision], and this is restoring vision.”
Retinal dystrophies lead to the loss of retinal pigment epithelium (RPE) and photoreceptors that capture light. However, bipolar and ganglion cells, which are “the wire to the (Read more...)